塞马鲁肽对普拉德-威利综合征和 2 型糖尿病患者体重减轻和血糖控制的影响

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion Pub Date : 2024-02-01 DOI:10.1016/j.endien.2023.12.001

Olga Giménez-Palop , Ana Romero , Laia Casamitjana , Rocio Pareja , Mercedes Rigla , Assumpta Caixàs

{"title":"塞马鲁肽对普拉德-威利综合征和 2 型糖尿病患者体重减轻和血糖控制的影响","authors":"Olga Giménez-Palop , Ana Romero , Laia Casamitjana , Rocio Pareja , Mercedes Rigla , Assumpta Caixàs","doi":"10.1016/j.endien.2023.12.001","DOIUrl":null,"url":null,"abstract":"<div><p>Prader–Willi Syndrome (PWS) is the most common genetic cause of obesity, occurring in approximately 1 in 15,000 newborns. It results from the lack of expression of genes on the paternal allele of the chromosomal region 15q-11q13 (65–75% due to type 1 or type 2 deletion). Individuals with PWS experience associated symptoms such as hypotonia, hyperphagia, and early-onset obesity (before 5 years of age). Around 20% of adults with PWS also develop type 2 diabetes. Previous studies have shown the beneficial effects of GLP1-RA medications, such as exenatide and liraglutide, in treating type 2 diabetes in PWS. However, there is limited information available on the use of semaglutide in PWS. This study aimed to evaluate the effects of semaglutide on weight loss and glycaemic control in four patients with PWS and type 2 diabetes associated with obesity. The patients were started on weekly subcutaneous progressive doses of semaglutide.</p></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"71 2","pages":"Pages 83-87"},"PeriodicalIF":1.8000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of semaglutide on weight loss and glycaemic control in patients with Prader–Willi Syndrome and type 2 diabetes\",\"authors\":\"Olga Giménez-Palop , Ana Romero , Laia Casamitjana , Rocio Pareja , Mercedes Rigla , Assumpta Caixàs\",\"doi\":\"10.1016/j.endien.2023.12.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Prader–Willi Syndrome (PWS) is the most common genetic cause of obesity, occurring in approximately 1 in 15,000 newborns. It results from the lack of expression of genes on the paternal allele of the chromosomal region 15q-11q13 (65–75% due to type 1 or type 2 deletion). Individuals with PWS experience associated symptoms such as hypotonia, hyperphagia, and early-onset obesity (before 5 years of age). Around 20% of adults with PWS also develop type 2 diabetes. Previous studies have shown the beneficial effects of GLP1-RA medications, such as exenatide and liraglutide, in treating type 2 diabetes in PWS. However, there is limited information available on the use of semaglutide in PWS. This study aimed to evaluate the effects of semaglutide on weight loss and glycaemic control in four patients with PWS and type 2 diabetes associated with obesity. The patients were started on weekly subcutaneous progressive doses of semaglutide.</p></div>\",\"PeriodicalId\":48650,\"journal\":{\"name\":\"Endocrinologia Diabetes Y Nutricion\",\"volume\":\"71 2\",\"pages\":\"Pages 83-87\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrinologia Diabetes Y Nutricion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2530018024000222\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinologia Diabetes Y Nutricion","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2530018024000222","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

普拉德-威利综合征（Prader-Willi Syndrome，PWS）是导致肥胖最常见的遗传病因，每 15,000 名新生儿中就有约 1 人患此病。它是由于染色体区域 15q-11q13 的父系等位基因缺乏表达（65%-75% 是由于 1 型或 2 型缺失）造成的。患有 PWS 的患者会出现肌张力低下、多食和早发肥胖（5 岁前）等相关症状。约 20% 的成年 PWS 患者还会患上 2 型糖尿病。以往的研究表明，GLP1-RA 药物（如艾塞那肽和利拉鲁肽）对治疗 PWS 患者的 2 型糖尿病有良好效果。然而，目前关于在PWS中使用塞马鲁肽的信息还很有限。本研究旨在评估塞马鲁肽对四名患有PWS并伴有肥胖的2型糖尿病患者的体重减轻和血糖控制效果。患者开始每周皮下注射渐进剂量的塞马鲁肽。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Effect of semaglutide on weight loss and glycaemic control in patients with Prader–Willi Syndrome and type 2 diabetes

Prader–Willi Syndrome (PWS) is the most common genetic cause of obesity, occurring in approximately 1 in 15,000 newborns. It results from the lack of expression of genes on the paternal allele of the chromosomal region 15q-11q13 (65–75% due to type 1 or type 2 deletion). Individuals with PWS experience associated symptoms such as hypotonia, hyperphagia, and early-onset obesity (before 5 years of age). Around 20% of adults with PWS also develop type 2 diabetes. Previous studies have shown the beneficial effects of GLP1-RA medications, such as exenatide and liraglutide, in treating type 2 diabetes in PWS. However, there is limited information available on the use of semaglutide in PWS. This study aimed to evaluate the effects of semaglutide on weight loss and glycaemic control in four patients with PWS and type 2 diabetes associated with obesity. The patients were started on weekly subcutaneous progressive doses of semaglutide.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Endocrinologia Diabetes Y Nutricion Multiple-

CiteScore

2.10

自引率

10.50%

发文量

期刊介绍： Endocrinología, Diabetes y Nutrición is the official journal of the Spanish Society of Endocrinology and Nutrition (Sociedad Española de Endocrinología y Nutrición, SEEN) and the Spanish Society of Diabetes (Sociedad Española de Diabetes, SED), and was founded in 1954. The aim of the journal is to improve knowledge and be a useful tool in practice for clinical and laboratory specialists, trainee physicians, researchers, and nurses interested in endocrinology, diabetes, nutrition and related disciplines. It is an international journal published in Spanish (print and online) and English (online), covering different fields of endocrinology and metabolism, including diabetes, obesity, and nutrition disorders, as well as the most relevant research produced mainly in Spanish language territories. The quality of the contents is ensured by a prestigious national and international board, and by a selected panel of specialists involved in a rigorous peer review. The result is that only manuscripts containing high quality research and with utmost interest for clinicians and professionals related in the field are published. The Journal publishes Original clinical and research articles, Reviews, Special articles, Clinical Guidelines, Position Statements from both societies and Letters to the editor. Endocrinología, Diabetes y Nutrición can be found at Science Citation Index Expanded, Medline/PubMed and SCOPUS.